Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Stock Performance

Pulmatrix stock opened at $5.91 on Thursday. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $8.44. The company has a market capitalization of $21.57 million, a P/E ratio of -2.24 and a beta of 1.53. The stock has a 50-day simple moving average of $3.74 and a 200-day simple moving average of $2.64.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.